Objective-Vascular remodeling occurs after endothelial injury, resulting in smooth muscle cell (SMC) proliferation and vascular fibrosis. We previously demonstrated that the blood pressure-regulating hormone aldosterone enhances vascular remodeling in mice at sites of endothelial injury in a placental growth factor-dependent manner. We now test the hypothesis that SMC mineralocorticoid receptors (MRs) directly mediate the remodeling effects of aldosterone and further explore the mechanism. Approach and Results-A wire-induced carotid injury model was performed in wild-type mice and mice with inducible SMC-specific deletion of the MR. Aldosterone did not affect re-endothelialization after injury in wild-type mice. Deletion of SMC-MR prevented the 79% increase in SMC proliferation induced by aldosterone after injury in MR-Intact littermates. Moreover, both injury-induced and aldosterone-enhanced vascular fibrosis were attenuated in SMC-specific MR knockout mice. Further exploration of the mechanism revealed that aldosterone-induced vascular remodeling is prevented by in vivo blockade of the placental growth factor-specific receptor, type 1 vascular endothelial growth factor receptor (VEGFR1), the receptor for placental growth factor. Immunohistochemistry of carotid vessels shows that the induction of VEGFR1 expression in SMC after vascular injury is attenuated by 72% in SMC-specific MR knockout mice. Moreover, aldosterone induction of vascular placental growth factor mRNA expression and protein release are also prevented in vessels lacking SMC-MR. Conclusions-These studies reveal that SMC-MR is necessary for aldosterone-induced vascular remodeling independent of renal effects on blood pressure. SMC-MR contributes to induction of SMC VEGFR1 in the area of vascular injury and to aldosterone-enhanced vascular placental growth factor expression and hence the detrimental effects of aldosterone are prevented by VEGFR1 blockade. This study supports exploring MR antagonists and VEGFR1 blockade to prevent pathological vascular remodeling induced by aldosterone. (Arterioscler Thromb Vasc Biol. 2014;34:355-364 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
V ascular remodeling occurs in response to endothelial damage and contributes to vascular pathologies, including vascular stiffness due to hypertension or aging, atherosclerosis, vein graft failure, restenosis after percutaneous vascular procedures, and cardiac transplant vasculopathy. 1 Endothelial damage can be caused by mechanical injury or by cardiovascular risk factors, including dyslipidemia, hypertension, diabetes mellitus, or smoking. In the area of endothelial damage, the normally quiescent smooth muscle cells (SMCs) proliferate and produce extracellular matrix that contributes to vascular thickening and fibrosis. Although much has been learned about mechanisms of vascular remodeling, our current cardiovascular therapies are still limited by adverse remodeling that contributes to myocardial infarction, stroke, and the high failure rate of vein grafts, transplants, and even stents. Thus, there remains a need to identify novel contributors to vascular remodeling that might be more effective targets to prevent adverse cardiovascular events and improve the efficacy of our interventions.
Aldosterone is a steroid hormone that regulates blood pressure (BP) by acting on renal mineralocorticoid receptors (MRs) to induce genes in the kidney that promote sodium retention. 2 MR antagonists, including spironolactone and eplerenone, are used to treat hypertension and heart failure and significantly reduce cardiovascular mortality in randomized trials. [3] [4] [5] [6] Additional clinical data suggest that aldosterone promotes atherosclerotic ischemic events, including myocardial infarction and stroke, and increases mortality. 7, 8 In animal models of vascular injury, aldosterone enhances vascular remodeling. 9, 10 Conversely, MR antagonists decrease vascular remodeling in animal models of hypertension, 11 February 2014 balloon injury, 10 stent implantation, 12 vein grafting, 13 and hyperlipidemia-induced atherosclerosis. 14 Thus, aldosterone plays an important role in vascular remodeling that has been attributed largely to BP elevation with secondary vascular consequences. However, recently, it has become clear that aldosterone also has extrarenal actions. MR is expressed in vascular SMCs and endothelial cells (ECs) where it regulates genes involved in vascular inflammation, fibrosis, and calcification. [15] [16] [17] [18] [19] Indeed, we have demonstrated recently in a mouse model with inducible, SMC-specific MR deletion that SMC-MR directly contributes to vascular contractile function and BP elevation with aging. 20 In humans, the cardiovascular protective effects of MR antagonists exceed the expected effects of modest changes in systemic BP. 3, 4, 21 These clinical and experimental findings support the possibility that aldosterone could act directly on MR in the vasculature to contribute to vascular remodeling. If so, understanding the vascular cellular target that mediates aldosterone-enhanced remodeling (ECs versus SMCs) and the potential molecular downstream mechanisms could provide novel therapeutic strategies.
The vascular endothelial growth factors (VEGFs) are a family of secreted proteins that contribute to angiogenesis. VEGFs modulate vascular SMC and EC function via transmembrane VEGF type 1 and type 2 receptors (VEGFR1 and VEGFR2). 22 We previously discovered that aldosterone specifically regulates vascular expression of the VEGF family member, placental growth factor (PlGF), 9, 18 and that PlGF is necessary for aldosterone-enhanced vascular remodeling. 9 PlGF specifically binds to VEGFR1, whereas other VEGFs signal through both receptors. 22 In injured mouse vessels and in human vessels with atherosclerotic disease, aldosterone further enhances PlGF expression and specifically upregulates VEGFR1. 9 These data identify PlGF/ VEGFR1 as a potential mediator of aldosterone-enhanced vascular remodeling. In this study, we test the hypothesis that SMC-MR directly mediates the remodeling effects of aldosterone on injured vessels and further explore the role of PlGF/VEGFR1 as a potential downstream mechanism and therapeutic target to prevent aldosterone-enhanced vascular remodeling in vivo.
Materials and Methods
Materials and Methods are available in the online-only Supplement. 20
Results

Aldosterone Does Not Alter the Rate of Re-Endothelialization After Vascular Injury
We set out to explore the mechanism by which aldosterone infusion enhances vascular remodeling specifically at sites of vascular injury without significantly changing BP. 9 It has been suggested that the rate of endothelial regrowth after arterial injury determines the degree of vascular remodeling with accelerated re-endothelialization leading to an attenuated injury response. 23 Thus, we first examined the effect of aldosterone on the rate of re-endothelialization in a mouse carotid wire injury model. In this model, an aldosterone or vehicle infusion pump is inserted 1 day before carotid endothelial denudation by wire injury ( Figure 1A ). After wire-induced carotid injury, Evans blue dye is infused to mark the areas of denuded carotid endothelium. Representative images of injured carotid arteries immediately after the initial injury (day 0) and 1, 2, 3, 7, and 14 days after injury are shown in Figure 1B . Evans blue staining confirms complete denudation of the endothelium on day 0. Complete re-endothelialization of the artery is confirmed 14 days after injury. Quantification of the residual denuded area reveals no significant difference in the percentage of area covered with endothelium in arteries from aldosterone compared with vehicle-treated mice at all time points after injury ( Figure 1C ). These results suggest that aldosterone is not enhancing the vascular remodeling response by altering EC proliferation or migration and may instead be acting on MR elsewhere in the vessel so we next focused on the SMCs.
Aldosterone Enhances Vascular Injury by Direct, BP-Independent Effects on SMC-MR
The role of SMC-MR in aldosterone-stimulated vascular injury was examined directly using a mouse model with MR genetically deleted in adulthood specifically from SMC (SMC-MR-KO) compared with MR-intact littermate controls. 20 Prior studies reveal that at 3 months, SMC-MR-KO mice have no significant difference in systemic BP with or without aldosterone infusion when compared with MR-intact controls as measured by telemetry. 20 This is confirmed by tail-cuff plethysmography in the specific mice used for carotid injury that cannot have concurrent telemetry (Table) . Mice underwent the carotid injury protocol ( Figure 1A ) with insertion of a bromodeoxyuridine infusion pump at the time of injury to mark proliferating cells, and vascular remodeling was quantified 14 days after injury. Aldosterone was infused at a low dose that increases circulating aldosterone levels significantly and similarly in both genotypes to levels consistent with those seen in patients with cardiovascular disease. This had no effect on systolic BP or body weight in the mice (Table) . In uninjured vessels, there is minimal SMC proliferation, as measured by medial bromodeoxyuridine positive nuclei, regardless of the presence of SMC-MR or exogenous aldosterone consistent with the lack of effect of aldosterone on remodeling in the absence of endothelial damage. Vascular injury enhances SMC proliferation, even in the absence of SMC-MR (P<0.001 for injured versus uninjured), thus all further comparisons are made between the injured vessels only. In MR-intact mice, aldosterone significantly enhances SMC proliferation after injury (Figure 2A ), as we previously published in wild-type C57Bl/6 mice. 9 However, aldosterone fails to promote SMC proliferation in SMC-MR-KO mice (Figure 2A ). Aldosterone infusion also significantly enhances injury-induced vascular fibrosis in MR-intact mice but not in SMC-MR-KO mice ( Figure 2B ). Interestingly, even in the absence of excess aldosterone, SMC-MR deficiency attenuates vascular fibrosis, supporting the concept that SMC-MR contributes to the fibrotic response to vascular injury in the presence of physiological and pathological levels of aldosterone ( Figure 2B ). Finally, vascular injury causes an increase in vessel medial area that is enhanced in the presence of excess aldosterone in MR-intact but not in SMC-MR-KO mice ( Figure 2C ). Taken together, these data support the new concept that aldosterone enhances vascular remodeling by direct effects on MR in SMCs and that SMC-MR contributes to basal and aldosterone-enhanced vascular fibrosis in this injury model.
VEGFR1 Blockade Prevents Aldosterone-Enhanced Vascular Remodeling In Vivo
We previously demonstrated that aldosterone-induced vascular remodeling is dependent on the presence of the growth factor PlGF 9 that binds specifically to VEGFR1. To explore the role of VEGF receptors in aldosterone-induced (Figure 3 ). VEGFR1-blocking antibody, but not VEGFR2blocking antibody, prevents aldosterone-enhanced SMC proliferation ( Figure 3A ), vascular fibrosis ( Figure 3B ), and medial thickening ( Figure 3C ). Taken together, these data suggest that VEGFR1 plays a significant and specific role in aldosterone-enhanced vascular remodeling in vivo.
Because the carotid injury studies in Figures 2 and 3 implicate direct effects of aldosterone on SMC-MR in promoting cell proliferation, we attempted to explore the mechanism using an in vitro model of mouse carotid SMC proliferation. Aldosterone enhances proliferation of primary mouse carotid SMCs in a dose-dependent manner ( Figure IA in the online-only Data Supplement) as it does for other cultured SMCs. 24 However, at physiologically (1 nmol/L) and pathologically (5-10 nmol/L) relevant aldosterone concentrations, the increase in proliferation in vitro is modest (<20%) and much less than the enhanced proliferative response to the same concentration of aldosterone in vivo (70%-80%). Further studies revealed that aldosterone treatment of cultured primary mouse carotid SMCs results in a nonsignificant trend toward increased PlGF expression (much less than the 300% increase in whole vessels 9 ) and only a modest but significant increase in VEGFR1 expression that is prevented by cotreatment with the MR-specific antagonist eplerenone ( Figure IB in the online-only Data Supplement). In vitro, VEGFR1 blockade inhibits the modest aldosteroneenhanced SMC proliferation, whereas VEGFR2 blockade prevents a significant aldosterone-induced increase in proliferation but is not significantly decreased when compared with aldosterone with IgG ( Figure IC in the online-only Data Supplement). We conclude that although the PlGF/VEGFR1 pathway is modestly activated by aldosterone and contributes to carotid SMC proliferation in vitro, this in vitro system does not completely recapitulate the effect of aldosterone on the proliferative response to injury in vivo. Therefore, further exploration of the mechanism was performed in vivo and in whole vessels.
SMC-MR Contributes to VEGFR1 Induction on SMCs After Vascular Injury
In healthy vessels, VEGFR1 is expressed exclusively in the endothelium; however, upon vascular injury, VEGFR1 expression is activated on vascular SMCs by unclear mechanisms. 25 To examine the vascular compartments in which VEGFR1 is expressed in the wire injury model, immunohistochemistry with VEGFR1-specific antibody was performed on uninjured and injured carotid arteries 14 days after unilateral endothelial injury. In this model, we confirm that uninjured vessels express VEGFR1 only in the endothelium, whereas VEGFR1 is expressed robustly on ECs and SMCs in injured vessels even without exogenous aldosterone administration ( Figure 4A ). Serial sections incubated with CD31 (an EC marker) and SMC-α actin (a SMC marker) are included in Figure 4A to confirm the identity of each cell type in the vessel.
To explore whether SMC-MR is involved in the mechanism of the injury-induced SMC expression of VEGFR1, medial VEGFR1 immunoreactivity was quantified in serial sections of the injured vessels from the study in Figure 2 (Figure 4B ). VEGFR1 expression is detected in the media in all the injured vessels; however, in vessels from SMC-MR-KO, there is a significant and substantial reduction in the percentage of the vessel staining positive for VEGFR1 regardless of the presence of excess aldosterone. Taken together, these data support that SMC-MR contributes substantially to the induction of VEGFR1 expression on SMCs after a vessel is injured.
SMC-MR Is Necessary for Aldosterone Induction of Vascular PlGF
We previously demonstrated that aldosterone stimulates vascular PlGF transcription and release from intact and injured mouse vessels and from diseased human vessels. 9 To investigate whether PlGF production is dependent on SMC-MR, whole vessels from MR-intact and SMC-MR-KO mice were treated with aldosterone ex vivo and PlGF levels were assessed. In MR-intact vessels, aldosterone increases vascular PlGF mRNA and extravascular PlGF protein >3-fold ( Figure 5 ) as previously demonstrated in wild-type vessels. 9 In vessels lacking SMC-MR, the aldosterone-induced increase in PlGF message and protein secretion are prevented, demonstrating that aldosterone regulation of vascular PlGF requires SMC-MR. Thus, deletion of SMC-MR attenuates the local upregulation of VEGFR1 at the site of injury ( Figure 4B) , prevents aldosterone-induced vascular PlGF production ( Figure 5) , and prevents aldosterone-enhanced vascular remodeling after injury (Figure 2 ).
Discussion
In summary, we have demonstrated that SMC-MR is required for aldosterone-enhanced vascular remodeling in vivo. Aldosterone induces vascular SMC proliferation and fibrosis after injury without affecting endothelial regrowth. These adverse effects of the hormone are completely lost in mice with the MR specifically deleted from SMCs in adulthood. SMC-MR also contributes to injury-associated vascular fibrosis even without addition of exogenous aldosterone. Blockade of VEGFR1 signaling with receptor-specific antibodies also prevents aldosterone-induced SMC proliferation and vascular fibrosis after injury in vivo. Further mechanistic studies reveal that SMC-MR directly contributes to the induction of VEGFR1 expression on SMCs at the site of vascular injury and is necessary for aldosterone induction of the VEGFR1 ligand, PlGF.
Putting these data together with previously published work 9,18,25 provides a new model by which SMC-MR contributes directly to vascular remodeling ( Figure 6 ). This model addresses the longstanding conundrum as to why aldosterone alone has no adverse vascular phenotype unless combined with a cause for endothelial dysfunction, including high salt intake, 26 congestive heart failure, 27 hyperlipidemia, 28 or localized vascular injury. 9 In healthy vessels with an intact endothelium, VEGFR1 is expressed only on ECs and aldosterone activation of SMC-MR only modestly Smooth muscle cell-mineralocorticoid receptor (SMC-MR) contributes to injury-induced SMC expression of the type 1 vascular endothelial growth factor receptor (VEGFR1). A, VEGFR1 is expressed exclusively on endothelial cells in uninjured vessels and is induced on SMC after vascular injury. Immunohistochemistry of serial carotid artery sections 14 days after unilateral carotid injury of wild-type mice using VEGFR1 antibody to localize expression. Anti-CD31 antibody identifies endothelial cells, and anti-smooth muscle α-actin antibody identifies SMC. B, SMC-MR contributes to induction of SMC VEGFR1 expression after endothelial injury. VEGFR1 immunohistochemistry of sections of injured carotids from MR-intact and SMC-MR-KO littermates 14 days after injury. Representative carotid artery sections are shown on the left and the percentage of the medial area that stains positive for VEGFR1 is quantified on the right. Scale bar, 0.5 mm. n=8. *P<0.05 vs MR-intact vehicle-and aldosterone-treated vessels.
increases PlGF transcription and release 9 with no effect on SMC proliferation and fibrosis as PlGF receptors are not expressed on SMCs under these conditions (Figure 6 , left). Thus in healthy vessels, aldosterone does not disrupt the quiescent SMC phenotype and vessels do not undergo adverse remodeling even when aldosterone levels are high (eg, in healthy individuals [or mice] on a low sodium diet). However, when vessels are injured or diseased, SMC-MR contributes to substantial upregulation of PlGF 9, 18 and to the expression of VEGFR1 on SMCs resulting in SMC proliferation and vascular fibrosis. 25, 29 Conversely, PlGF deficiency 9 or VEGFR1 blockade prevents aldosterone-enhanced remodeling after injury in mice. These data from mouse models are consistent with human data demonstrating that aldosterone enhances PlGF and VEGFR1 expression in vessels from patients with severe atherosclerosis (undergoing coronary artery bypass grafting) but not in healthy human vessels (transplant donors). 9 Based on these data, we propose the model in Figure 6 (right) that in diseased or injured vessel, SMC-MR locally enhances PlGF release and SMC VEGFR1 expression resulting in enhanced SMC proliferation, vascular fibrosis, and vessel thickening after injury. By this mechanism, aldosterone and SMC-MR promote adverse vascular remodeling that contributes to luminal narrowing and vascular stiffness, important contributors to cardiovascular disease. Treatment of diseased human vessels with the MR antagonist spironolactone ex vivo suppresses PlGF production, 9 thus inhibition of this mechanism may contribute to the beneficial effects of MR antagonists in cardiovascular patients. 3, 4, 6 Specific inhibition of VEGFR1 prevented aldosterone-enhanced remodeling in vivo supporting the concept that SMC-MR-regulated pathways could be targeted to prevent or treat cardiovascular diseases.
For more than half a century, aldosterone and MR have been known to regulate BP by renal sodium retention. Based on this knowledge, the detrimental cardiovascular effects of aldosterone have been attributed to secondary vascular responses to elevated BP. In this study, the low-dose aldosterone infusion enhanced vascular remodeling without increasing BP. Moreover, aldosterone-enhanced vascular remodeling is completely prevented by the specific deletion of MR from SMCs. We previously demonstrated that SMC-MR-KO mice have intact renal MR function, normal renal sodium handling, and no difference in telemetric BP at the age used for this study, 20 which we confirm by tail-cuff BP here. The use of an inducible model of MR deletion also prevents developmental effects of MR deletion from contributing to altered vascular remodeling responses. Taken together, these results support a new paradigm in which direct MR activation in the SMCs of the vasculature is responsible for enhanced vascular remodeling independent of renal MR and BP alterations.
There are several limitations and future directions to this study that should be noted. First, the wire carotid injury model in C57Bl/6 mice is a reproducible model to examine medial SMC proliferation and collagen deposition in the vessel wall. These processes are paramount in vascular remodeling induced by hypertension and aging and also occur in the setting of atherosclerosis and vascular injury in which proliferation is accompanied by SMC migration and neointima formation. Aldosterone contributes to neointimal formation in other models, 10 but this occurs only rarely in the wire injury model in C57Bl/6 mice (<10% of mice). Thus, the direct role of SMC-MR, PlGF, and VEGFR1 in neointima formation warrants further exploration in vascular injury models with more reproducible neointimal responses. This would have important clinical implications because the aldosterone-enhanced mechanism of vascular remodeling identified here seems to dissociate SMC proliferation from endothelial regrowth, a desired situation for drugs to prevent restenosis of vascular stents in which neointima formation is an important component of the pathology. PlGF and VEGF are also vasodilators and as a result, novel cancer therapeutics that block VEGF receptors cause hypertension 30 and further exploration of the role of VEGF signaling in vascular remodeling could have important implications for the growing patient populations treated with anti-VEGF therapy for malignancy and other conditions. In this study, we confirm that there is no substantial difference in tail-cuff BP at the concentrations of blocking antibodies or aldosterone used. Telemetric monitoring is the gold standard for BP measurements in rodents; however, because the catheter is inserted via the carotid artery, this cannot be performed concurrently with carotid injury. We previously demonstrated by telemetry that there is no BP difference in young SMC-MR-KO mice compared with MR-intact controls at baseline or with aldosterone infusion. 20 Here, we confirm by tail-cuff plethysmography that the substantial changes in arterial remodeling responses are not because of large changes in BP although small BP differences (≤5-10 mm Hg) cannot be accurately distinguished by this technique. Finally, understanding how the downstream signaling of MR and VEGFR1 converge in SMCs to coordinate the proliferative response to injury is an important area for future investigation. Indeed, both MR 24 and VEGFR1 25 signaling have been shown to promote SMC proliferation by activation of mitogen activated protein-kinase signaling in vitro. Because the SMC-MR/PlGF/VEGFR1 mechanism identified here is specifically activated in the setting of vascular injury that is not easily reproduced in vitro, future in vivo studies will be important to explore the downstream signaling events that mediate aldosterone-induced vascular remodeling.
In conclusion, these data support a novel mechanism of aldosterone-enhanced remodeling in which direct activation of SMC-MR promotes adverse vascular remodeling by regulation of VEGFR1 and PlGF in SMCs in areas of vascular injury. This mechanism is independent of alterations in endothelial regrowth, renal MR activation, and systemic BP. Clinically, elevated serum aldosterone is increasingly common because of an association with resistant hypertension, 31 heart failure, and obesity 32 and aldosterone levels correlate with increased risk of myocardial infarction, stroke, and death. 7 Furthermore, SMC-MR activation contributes to vascular fibrosis in this model even without added aldosterone and hence might contribute to vascular remodeling even in patients with normal serum aldosterone levels. Interestingly, the basal level of vascular fibrosis after injury is not significantly altered by VEGFR1 blockade, supporting an additional mechanism by which SMC-MR contributes to fibrosis that remains to be explored. Thus, the mechanisms identified in Figure 6 . Model for the role of the smooth muscle cell-mineralocorticoid receptor (SMC-MR)/placental growth factor (PlGF)/type 1 vascular endothelial growth factor receptor (VEGFR1) pathway in aldosterone-induced vascular remodeling after injury. In the healthy uninjured vasculature (left), VEGFR1 is expressed exclusively on endothelial cells (ECs) and not on SMCs. Aldosterone activation of SMC MRs in this setting modestly enhances PlGF transcription and local release that can act only on EC-expressing VEGFR1. Thus in healthy vessels, aldosterone does not disrupt the quiescent SMC phenotype and vessels do not undergo adverse remodeling even when aldosterone levels are high. In the setting of vascular injury or disease (right), SMC-MR contributes to local upregulation of VEGFR1 expression on SMC and aldosterone activation of SMC-MR contributes to substantial PlGF expression and release. PlGF mediates aldosterone-enhanced SMC proliferation and vascular fibrosis after injury by binding to VEGFR1 receptors on SMC. This model provides insight into how aldosterone acts synergistically with endothelial injury to contribute to adverse vascular remodeling and how MR antagonists prevent adverse cardiovascular events in clinical trials.
this study likely contribute to vascular remodeling in rapidly growing populations of patients at high risk for cardiovascular disease and have important implications for developing new therapeutic strategies to treat vascular diseases. Current aldosterone antagonists therapies are limited by off-target (gynecomastia) and renal (hyperkalemia) side effects. Thus, understanding the mechanisms by which vascular MR activation contributes directly to vascular disease could identify novel targets, including the PlGF/VEGFR1 pathway, which could reap the vascular benefits of MR blockade without the systemic side effects.
